WINSTON-SALEM, N.C., Feb. 5 /PRNewswire-FirstCall/ -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will be presenting at the 9th Annual BIO CEO and Investor Conference at the Waldorf-Astoria Hotel in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO ) On Monday, February 12 at 12:30 p.m., Dr. deBethizy will give a corporate presentation. This presentation will be webcast and accessible from the Investor Relations section of the Company's website, http://www.targacept.com/. The webcast will also be available for replay on the Company's website for two weeks following the corresponding conference. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
Dr. deBethizy is also scheduled to participate in other aspects of the conference. He will be included in a roundtable discussion entitled "Doing a Transformative Deal" designed to explore how life science companies achieve validation and financial foundation through first deals, transforming themselves in the process and laying a foundation for subsequent valuations. He will also be a panelist on a therapeutic workshop entitled, "Baby Boomers - Where Are the Growth Market Opportunities?" designed to explore what companies are doing to improve the quality of life of aging Americans.
About Targacept Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system activity to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, depression and anxiety disorders, and multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina. DATASOURCE: Targacept, Inc.
CONTACT: Alan Musso, VP and CFO of Targacept, Inc., +1-336-480-2186, or , or Michelle Linn, Linnden Communications for Targacept, Inc., +1-508-419-1555, or Web site: http://www.targacept.com/
|